Doxepin in the treatment of chronic urticaria.
24 patients were included in a double-blind, crossover trial to test the efficacy of doxepin (a tricyclic antidepressant) and mequitazine (a new antihistamine of the phenothiazine group). Compared to placebo treatment, both doxepin and mequitazine significantly improved the various clinical parameters evaluated. When the two active drugs were compared with each other, no significant difference in their effectiveness was found. The authors conclude that both agents are equally useful in the treatment of chronic idiopathic urticaria.
Harto
A
A
Sendagorta
E
E
Ledo
A
A
D000293:Adolescent; D000328:Adult; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004316:Doxepin / Q000627:therapeutic use*; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010640:Phenothiazines / Q000627:therapeutic use; D014581:Urticaria / Q000188:drug therapy*
D006634:Histamine H1 Antagonists; D010640:Phenothiazines; D004316:Doxepin; C006069:mequitazine